This activity already occurred and is no longer available.
Integrated Care Strategies to Address the Impact of Residual Symptoms on Functional Outcomes in MDD
This activity offers new perspectives on treating MDD.

Integrated Care Strategies to Address the Impact of Residual Symptoms on Functional Outcomes in MDD

Roger S. McIntyre, MD, FRCPC; Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA; Gregory W. Mattingly, MD

Depression is one of the leading causes of disability worldwide. It affects individuals, families, businesses, and society and is common in patients seeking care in the primary care setting. Approximately 55% of patients will respond to treatment with the initial antidepressant.1 Yet, even in those patients who respond to treatment and achieve remission, residual symptoms can significantly inhibit functionality and increase the risk of relapse and recurrence.2

This symposium on MDD features expert faculty offering new perspectives on treating this pervasive disorder, highlights residual symptoms as a challenge to clinicians, and ways to engage with patients to optimize management of all symptoms.

References:
1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D, implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
2. Zajecka JM. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry. 2013;74(Suppl 2):9-13.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:

  • Recognize the relationship between residual cognitive symptoms and functional impairment in patients with MDD.
  • Assess all of the symptoms of MDD including cognitive and residual symptoms with a validated screening tool at each visit.
  • Engage patients in shared decision-making to optimize their treatment options to manage all symptoms of MDD.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 2.0 AAPA Category 1 CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until October 31, 2018.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Faculty

Roger S. McIntyre, MD, FRCPC (Moderator)
Professor of Psychiatry and Pharmacology
University of Toronto
Executive Director
Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, ON
Disclosures: Receives research grants from Allergan; AstraZeneca; Janssen Pharmaceuticals Inc.; Lundbeck; Otsuka; Pfizer Inc.; Purdue Pharma; and Shire. Serves on the advisory board for AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited. Receives speaker's fees from AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA
Clinical Assistant Professor
Department of PA Studies
UT Southwestern Medical Center School of Health Professions
PA
Mental Health and Behavioral Medicine
Parkland Health and Hospital System
Dallas, TX
Disclosures: Serves on the speakers bureau for Sunovion Pharmaceuticals Inc. Consultant for Sunovion Pharmaceuticals Inc.

Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
St. Louis, MO
President
Midwest Research Group
St. Charles, MO
Disclosures: Receives research grants from Akili; Alcobra Pharma; Alkermes; Allergan; Boehringer Ingelheim; Forum Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Medgenics, Inc.; NLS-1 Pharma AG; Reckitt Benckiser Group; Shire; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Serves as a consultant for Alkermes, Allergan, Forum Pharmaceuticals Inc.; Lundbeck; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Perdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Shire; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals. Receives speaker fee's from Allergan, Lundbeck, Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals.

Activity Planners

Eva Hardy, MS, RN, ANP-B (peer reviewer), Kashemi D. Rorie, PhD (planning committee), Sharon Tordoff, CHCP (planning committee), Jan Perez, CHCP (planning committee), have no disclosures to report.

CME Outfitters, LLC Staff Activity Planners

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Off-Label/Unapproved Product(s) Discussion

Faculty of this CME activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
421 Registered Users